Multiple forms of copper (II) co-ordination occur throughout the disordered N-terminal region of the prion protein at pH 7.4

Mark A. WELLS*†, Clare JELINSKA*, Laszlo L. P. HOSSZU*†, C. Jeremy CRAVEN*, Anthony R. CLARKE†, John COLLINGE†, Jonathan P. WALTHO* and Graham S. JACKSON†1

*Krebs Institute for Biomolecular Research, Department of Molecular Biology and Biotechnology, University of Sheffield, Sheffield S10 2TN, U.K., and †MRC Prion Unit, Department of Neurodegenerative Disease, Institute of Neurology, University College London, Queen Square, London WC1N 3BG, U.K.

Although the physiological function of the prion protein remains unknown, *in vitro* experiments suggest that the protein may bind copper (II) ions and play a role in copper transport or homoeostasis *in vivo*. The unstructured N-terminal region of the prion protein has been shown to bind up to six copper (II) ions, with each of these ions co-ordinated by a single histidine imidazole and nearby backbone amide nitrogen atoms. Individually, these sites have micromolar affinities, which is weaker than would be expected of a true cuproprotein. In the present study, we show that with subsaturating levels of copper, different forms of co-ordination will occur, which have higher affinity. We have investigated the copper-binding properties of two peptides representing the known copper-binding regions of the prion protein: residues 57–91, which contains four tandem repeats of the octapeptide GGGW-

GQPH, and residues 91–115. Using equilibrium dialysis and spectroscopic methods, we unambiguously demonstrate that the mode of copper co-ordination in both of these peptides depends on the number of copper ions bound and that, at low copper occupancy, copper ions are co-ordinated with sub-micromolar affinity by multiple histidine imidazole groups. At pH 7.4, three different modes of copper co-ordination are accessible within the octapeptide repeats and two within the peptide comprising residues 91–115. The highest affinity copper (II)-binding modes cause self-association of both peptides, suggesting a role for copper (II) in controlling prion protein self-association *in vivo*.

Key words: copper (II), equilibrium dialysis, prion protein (PrP), self-association.

INTRODUCTION

Prion diseases are a group of transmissible neurodegenerative disorders, found in both humans and animals, which have become the focus of intense scientific interest because of their apparently unique underlying biology [1]. The 'protein-only' hypothesis is now widely accepted and proposes that the causative agent of these diseases is largely, if not exclusively, composed of an abnormal conformer of a host-encoded protein known as the prion protein, PrP, and is devoid of nucleic acid [2,3]. Mature human PrP is a 209-residue polypeptide with a C-terminal glycosylphosphatidylinositol anchor and two glycosylation sites, that comprises a folded C-terminal domain and a flexibly disordered N-terminal region [4-6]. Although much is now known about the disease-causing properties of the prion protein, the physiological function of the protein remains an enigma. PrP is expressed in most tissues in adults, but the highest levels of expression occur in the central nervous system and the immune system [7,8]. Transgenic mice in which the *Prnp* gene has been disrupted and hence PrP^C (PrP cellular isoform) expression is ablated display no developmental or behavioural phenotype [9], although more detailed studies have described electrophysiological abnormalities [10] and alterations in sleep and circadian rhythms

In vitro experiments have revealed that the prion protein specifically binds copper (II) [12–15] and this had led to the proposal that PrP may function as a cuproprotein *in vivo*. However, the evidence for this assertion is limited; mice that do not express PrP have been reported to have reduced levels of copper (II) in membrane fractions from the brain [16], although this result

could not be replicated by other investigators [17]. Cultured cells induced to express PrP have been shown to have a higher copper-binding capacity than uninduced cells [18]. Copper (II) has also been reported to cause internalization of PrP, but the concentrations required to cause this effect are vastly above measured physiological levels [18,19].

A clear understanding of the copper (II)-binding properties of the prion protein in vitro is thus essential in order to critically evaluate proposals relating to any copper-binding role in vivo. The interaction of full-length and truncated forms of the prion protein with copper (II) has been investigated using a range of techniques including EPR [20-22], CD [23], X-ray crystallography [24], NMR [25,26], MS [14,15], Raman spectroscopy [27,28], FTIR (Fourier transform IR) spectroscopy [29] and potentiometry [30]. A consensus has emerged that, at maximum copper (II) occupancy, the prion protein can bind five or six copper ions, and that each of these ions is co-ordinated by a single histidine imidazole and two deprotonated backbone amide nitrogen atoms [14,21,24]. In this way, each of the four octapeptide repeats can bind a single ion, and sites at His96 and His111 can bind an additional two ions in a similar fashion [21,26]. It has, however, become clear that, at lower copper (II) occupancy, copper co-ordination by the octapeptide repeats is different to the total occupancy state. Three published works now report that, within the four octapeptide repeats, a single copper (II) ion can be co-ordinated by multiple histidine imidazoles without the involvement of backbone amides [25,30,31]. Most estimates of the affinity of PrP for copper have been in the low-micromolar range [15,23,32,33], but the affinity has also been placed dramatically higher, in the femtomolar range under idealized conditions [25]. In the absence of definitive in vivo

Abbreviations used: CSF, cerebrospinal fluid; ICP, inductively coupled plasma; NEM, N-ethylmorpholine; PrP, prion protein; PrP^C, PrP cellular isoform; PrP⁵⁷⁻⁹¹ and PrP⁹¹⁻¹¹⁵, peptides representing residues 57–91 and residues 91–115 of the human prion protein respectively; Cu₂(PrP⁵⁷⁻⁹¹), complex of PrP⁵⁷⁻⁹¹ with two copper ions; Cu(PrP⁹¹⁻¹¹⁵)₂, complex of a copper ion with two PrP⁹¹⁻¹¹⁵ molecules.

¹ To whom correspondence should be addressed (email g.s.jackson@prion.ucl.ac.uk).

experiments which might confirm that PrP is a true cuproprotein, *in vitro* affinity measurements offer an alternative route to assess whether this hypothesis is credible. *In vivo*, most extracellular copper is sequestered in complexes with proteins and amino acids which have affinities in the nanomolar-to-picomolar range [34,35], suggesting that, if PrP does have only a micromolar affinity for copper, it would be unlikely to bind copper under normal physiological conditions.

In the present study, we used equilibrium dialysis to thoroughly characterize the multiple modes of copper co-ordination which can occur in peptides representing residues 57-91 (PrP⁵⁷⁻⁹¹, containing the four octapeptide repeats) and residues 91-115 (PrP^{91–115}, containing His⁹⁶ and His¹¹¹) of the human prion protein. As well as allowing the determination of stoichiometry, this technique can be used to identify sites of different affinity through Scatchard analysis and provides a framework for the unambiguous interpretation of spectroscopic measurements. In order to keep copper (II) soluble above about pH 5, a chelating buffer must be used. As these buffers also compete against any interaction of copper (II) with the peptide, the experiment reports an apparent affinity that is weakened relative to the true value. In each case, the true dissociation constants has been calculated by determining the free copper concentration when the total copper concentration is the same as the apparent dissociation constant. We have used this information, in conjunction with CD, fluorescence and NMR spectroscopic measurements to characterize the multiple modes in which copper (II) can be co-ordinated by the PrP peptides. The data reveal that the affinities of the lower-occupancy copperbinding modes are in the nanomolar range. The present work demonstrates for the first time that multiple modes of copper (II) co-ordination can occur at the binding sites outside of the octapeptide repeats, and that self-association plays a role in the highest-affinity copper-binding mode of both peptides.

MATERIALS AND METHODS

Peptide synthesis and purification

Peptide synthesis was carried by ABC (Advanced Biotechnology Centre), Imperial College London, London, U.K. Peptides were produced by solid-phase stepwise synthesis using the Fmoc (fluoren-9-ylmethoxycarbonyl) N-terminal protection strategy. All peptide products were purified and analysed by reverse-phase HPLC. Molecular-mass determination was performed using MALDI (matrix-assisted laser-desorption ionization)-MS. Both peptides were acetylated at the N-terminus and amidated at the C-terminus. The peptide sequences used were PrP⁵⁷⁻⁹¹, WGQ-PHGGGWGQPHGGGWGQPHGGGWGQPHGGGWGQ, and PrP⁹¹⁻¹¹⁵, QGGGTHSQWNKPSKPKTNMKHMAGA.

Equilibrium dialysis

Solutions of peptides in 5 mM Tris/HCl, pH 7.4, 50 mM Mops, pH 7.4, or 10 mM acetate buffer, pH 5.5, were dialysed for approx. 10 h against a 1 litre reservoir of copper-containing buffer, using Spectra/Por 7 3500 MWCO (molecular-mass cut-off) dialysis membrane. Copper was added to each buffer reservoir from a stock of either 20 mM CuSO₄ or 20 mM CuSO₄ containing 40 mM glycine, to achieve the desired copper concentration. After dialysis, samples of the peptide solution and the dialysis buffer were diluted 5-fold with 1 % Aristar nitric acid, and the copper concentration then measured using a Spectro-Ciros CCD (charge-coupled device) ICP (inductively coupled plasma)-atomic emission spectrometer. Typically, final peptide concentrations were approx. 10 μ M for PrP⁵⁷⁻⁹¹ and approx. 40 μ M for PrP⁹¹⁻¹¹⁵.

Measurements of peptide concentrations

Peptide concentrations were determined by measuring the absorbance of solutions at 280 nm using the molar absorption coefficient of tryptophan at that wavelength. For experiments on PrP⁹¹⁻¹¹⁵ at pH 7.4, the contribution of peptide-bound copper to the molar absorption coefficient at 280 nm was significant. The molar absorption coefficient of copper (II) in the Cu₂(PrP⁹¹⁻¹¹⁵) complex (a complex of two copper ions with PrP⁹¹⁻¹¹⁵) was measured as 1700 M⁻¹ · cm⁻¹, and a similar value was obtained for the Cu(PrP⁹¹⁻¹¹⁵)₂ complex (a complex of a copper ion with two PrP⁹¹⁻¹¹⁵ molecules). The concentration of peptide bound copper was determined directly from the ICP-atomic emission spectrometry results, and thus the contribution of the peptide-bound copper to the absorbance at 280 nm could be calculated and subtracted from the raw data.

CD

Spectra were recorded on a Jasco J-810 spectropolarimeter at 25 °C, with a scanning speed of 10 nm/min and the slit width set to 150 μ m. The signal-to-noise ratio was limited in most samples and so, to average out noise as much as possible, the data pitch was set to 5 nm, the integration time to 30 s per point and the number of scans per spectrum to four. Aliquots of 2 or 20 mM CuSO₄ were added to peptide solutions in Tris and NEM (N-ethylmorpholine) buffers. For peptide samples in Mops buffer, copper was added as a glycine chelate either as 2 mM CuSO₄ and 4 mM glycine, or 20 mM CuSO₄ and 40 mM glycine. CD measurements in mdeg (θ) were converted into molar CD ($\Delta\varepsilon$, with units of litre·mol⁻¹·cm⁻¹) using the relationship $\Delta\varepsilon = \theta/(33\,000 \cdot l \cdot c)$, where c is the concentration in mol/l and l is the pathlength in cm.

Fluorescence spectroscopy

Experiments were carried out on a Cary Eclipse fluorimeter at 25 °C, with the excitation and emission wavelengths set to 280 nm and 356 nm respectively. The excitation slit width was 5 μm for all experiments. The emission slit width was 10 μm for experiments on PrP^{57–91} and 5 μm for PrP^{91–115}. The detector voltage was set to either 600 V or 800 V to bring the initial fluorescence of the sample into a measurable range. Peptide solutions were titrated with either 1 mM CuSO₄ in 5 mM Tris/HCl, pH 7.4 (for PrP^{91–115}). Data were corrected for the dilution of the sample.

NMR

 PrP^{57-91} samples contained 30 μ M peptide in 25 mM phosphate buffer, pH 7.4, and were titrated with aliquots of 200 μ M copper bisglycinate or 1 M Mops, pH 7.4. To exclude pH changes as a cause of the observed chemical-shift changes, the titration with Mops was repeated in 50 mM phosphate buffer, pH 7.4. The PrP^{91-115} sample contained 100 μ M peptide in 5 mM Tris/HCl, pH 7.4, and was titrated with 1 mM CuSO₄ in the same buffer. Both samples contained 5 % ²H₂O. Spectra of PrP⁵⁷⁻⁹¹ were recorded on a Bruker DRX-600 spectrometer, whereas spectra of PrP91-115 were recorded on a DRX-500 instrument. Both spectrometers were equipped with cryoprobes. Water suppression was achieved by pre-saturation of the water resonance. The recycle delay was set to allow complete relaxation of the peptide resonances between scans. For PrP⁵⁷⁻⁹¹, a 4 s recycle delay was used, whereas a 6 s delay was necessary for PrP91-115. All spectra were recorded at 25 °C.

Simulations of equilibria for formation of metal complexes and calculations of dissociation constants

Simulations were carried out using an in-house program to numerically calculate the equilibrium position of a series of linked equilibria, given fixed total concentrations of metal and ligand. In the simulations of binding to PrP^{57-91} shown in Figure 6, the four independent sites (termed mode C) were modelled using macroscopic dissociation constants of 0.25, 0.66, 1.5 and 4.0 μ M, likewise the two independent sites (termed mode B) were modelled using macroscopic dissociation constants of 125 and 500 nM.

To obtain the non-linear fits to the Scatchard plots shown in Figures 7(B) and 7(C), the $K_{\rm d}$ values were first crudely estimated by iteratively adjusting the $K_{\rm d}$ parameters in the model. The final fit was obtained by running a suite of simulations to sample, to one significant figure, all of the possible combinations of the two or three $K_{\rm d}$ parameters. For example, for the data in Figure 7(B), the parameters were set to: 10, 20, 30, 40 and 50 μ M for $K_{\rm d(1)}$; 3, 4, 5, 6 and 7 μ M for $K_{\rm d(2)}$; and 20, 30, 40 and 50 μ M for $K_{\rm d(3)}$, giving 100 data sets in total. The best fit to the observed data from these calculated data sets was then selected by least-squares fitting. The linear fits to the other Scatchard plots were also calculated by least-squares fitting.

The true dissociation constant of each peptide–copper complex is taken to be the concentration of free copper in the buffer solution when the total copper concentration is equal to the observed apparent dissociation constant. The acetate ion forms a 1:1 complex with copper (II), with a dissociation constant of 4.2 mM [36]. Since the acetate concentration is in excess of the copper concentration, the fraction of free copper in the acetate buffer can be calculated using the following relationship, which is derived from the standard binding equation for formation of a 1:1 complex:

$$\frac{M_{\rm free}}{M_{\rm total}} = 1 - \frac{L_{\rm free}}{K_{\rm d} + L_{\rm free}} \approx 1 - \frac{L_{\rm total}}{K_{\rm d} + L_{\rm total}} \ ({\rm when} \ L_{\rm total} \gg M_{\rm total})$$

where M_{free} is free metal concentration, M_{total} is total metal concentration, L_{free} is free ligand concentration, and L_{total} is total ligand concentration.

Glycine and Tris form 2:1 and 4:1 complexes with copper (II) respectively and so a mixture of different complexes is present in each case. The calculation of the free copper concentration in these buffers is more complex and had to be carried out using the same numerical model described above. Equilibria describing the formation of the $\text{Cu}(\text{Tris})_4$ complex and the copper bisglycinate complex were modelled using stepwise dissociation constants from the literature [36] adjusted for pH [37]. For Tris, these constants are 0.55, 1.0, 1.7 and 4.9 mM and for glycine, they are 1.2 and 12 μ M.

RESULTS

At maximum occupancy, PrP⁵⁷⁻⁹¹ binds four copper (II) metal ions

Titration of PrP^{57–91} with copper (II) in NEM buffer at pH 7.4 produces a complex with strong CD bands at 350 and 580 nm (Figure 1A). The CD signal saturates at a stoichiometry of 4:1. When the signal intensity is plotted against the quantity of copper added, it can be seen that the increase does not relate linearly to the quantity of copper (Figure 1B); the change in the CD signal on adding 1 molar equivalent of copper (II) is substantially smaller than for subsequent additions. These findings are in agreement with previous studies [20,23].




Figure 1 A Cu₄(PrP⁵⁷⁻⁹¹) complex is observed using CD

(A) Titration of 30 μ M PrP^{57–91} with CuSO₄ in 25 mM NEM buffer, pH 7.4, observed using CD, reveals a mode of copper binding which produces strong CD signals at 340 and 580 nm. Spectra are shown with 1–5 molar equivalents of copper (II) added. (B) Molar CD at 580 nm plotted against the mole fraction of copper added, showing that copper binding saturates at a stoichiometry of 4:1.

The choice of buffer is important in these experiments. Whereas NEM and other morpholine-based buffers interact only very weakly with copper (II) [37], buffers that compete more strongly for copper (II), such as Tris, will prevent formation of the CD-active complex at equivalent copper concentrations [23]. Accordingly, we have found that addition of 0.5 mM glycine in NEM buffer to the 4:1 complex at pH 7.4 abolishes approx. 80 % of the CD signal (results not shown). The fact that the four copper sites in the octapeptide repeats in PrP^{57–91} are not maintained in the presence of glycine is consistent with the reported low affinities which are in the micromolar range [15,23]. However, the absence of a substantial CD signal after the addition of 1 molar equivalent copper (II) to the peptide in NEM buffer does not preclude the existence of a single site of higher affinity.

PrP⁵⁷⁻⁹¹ co-ordinates a single copper (II) ion with higher affinity

Equilibrium dialysis shows that a single copper (II) ion will bind to PrP^{57–91} in Tris buffer at pH 7.4 (Figure 2A) with higher affinity than observed at additional sites. The apparent dissociation constant in 5 mM Tris buffer is $1.0 \pm 0.2 \mu M$, and using the association constants for the formation of a Cu(Tris)₄ complex [36], it can be calculated that $1 \mu M$ total copper (II) will give \sim 3 nM free copper (II) in this buffer. Thus the dissociation constant for the $Cu(PrP^{57-91})$ complex can be estimated as $3 \pm 2 \text{ nM}$ (apparent and true dissociation constants for PrP^{57–91} are summarized in Table 1). Using the equilibrium dialysis data, peptide samples can be prepared for spectroscopic analysis under conditions where the amount of bound copper is accurately known. In this case, the 1:1 complex was found to produce virtually no CD signal at visible wavelengths (Figure 2C), and the form of co-ordination present can therefore not resemble that observed at maximum occupancy. The data also show that further binding can occur in these conditions (Figure 2A), but with a substantially lower

A single copper (II)-binding site was also detected in acetate buffer at pH 5.5 (Figure 2B). In 10 mM acetate, the apparent dissociation constant is $13 \pm 2 \,\mu\text{M}$, and from this the dissociation constant of the Cu(PrP⁵⁷⁻⁹¹) at pH 5.5 can be calculated as $4 \pm 2 \,\mu\text{M}$. This 1:1 complex also has no detectable CD signal at 580 nm (Figure 2C), suggesting a mode of metal co-ordination indistinguishable from that observed at pH 7.4.




Figure 2 A 1:1 $Cu(PrP^{57-91})$ complex is revealed by equilibrium dialysis with a mode of binding distinct from that in the $Cu_4(PrP^{57-91})$ complex

Equilibrium dialysis of Prp⁵⁷⁻⁹¹ shows that the peptide binds a single copper (II) ion with greater affinity than subsequent ones. Scatchard plots show the fractional occupancy (ν) against ν /[CU_{Iree}], with the slope of the fitted lines giving the apparent association constant and the intercept on the x-axis giving the number of sites of this affinity. (**A**) Dialysis against CuSO₄ in 5 mM Tris buffer, pH 7.4, reveals a single high-affinity site (intercept = 0.86) with an apparent dissociation constant of $1.0 \pm 0.2~\mu$ M. Binding at a second site was observed under these conditions, but is substantially weaker. (**B**) A single-high affinity site (intercept = 1.03) is also present at pH 5.5 in 10 mM acetate buffer, with an apparent dissociation constant of $13 \pm 2~\mu$ M. (**C**) CD spectra show that these 1:1 complexes involve a different form of co-ordination the seen in the 4:1 complex. The spectra of the 1:1 complexes formed in 5 mM Tris buffer at pH 7.4 (15 μ M Prp⁵⁷⁻⁹¹ and 25 μ M CuSO₄, i.e. 1:1 CuSO₄ and 10 μ M free CuSO₄) and in 10 mM acetate of Prp⁵⁷⁻⁹¹ pH 5.5 (42 μ M Prp⁵⁷⁻⁹¹ and 300 μ M CuSO₄, i.e. 1:1 CuSO₄ and 240 μ M free CuSO₄) do not give any measurable CD bands, in contrast with the 4:1 complex formed in NEM buffer at pH 7.4.

Table 1 Apparent and real dissociation constants for PrP⁵⁷⁻⁹¹

pН	Buffer	Number of sites	K _d (app)	K _d (real)
7.4	5 mM Tris	1	$1.0\pm0.2~\mu\mathrm{M}$	3 ± 2 nM
5.5	10 mM Acetate	1	$13\pm2~\mu\mathrm{M}$	$4\pm2~\mu\mathrm{M}$
7.4	50 mM Mops	2	$6\pm2~\mu{ m M}$	$250 \pm 50 \text{ nM}$

The PrP⁵⁷⁻⁹¹ peptide forms a 1:1 complex with copper (II) in which all four histidine residues are co-ordinated

To investigate the nature of the 1:1 complex, a sample of PrP^{57–91} was titrated with copper (II) and observed by one-dimensional ¹H-NMR. Copper (II) is paramagnetic and will cause NMR signals from nearby nuclei to broaden to the point of becoming undetectable. The addition of copper caused specific simultaneous broadening of all histidine imidazole resonances in PrP^{57–91} (Figure 3). This indicates that all four histidine side chains in the peptide are involved in co-ordinating the first copper (II)




Figure 3 One-dimensional NMR of the $Cu(PrP^{57-91})$ complex

The Cu(PrP⁵⁷⁻⁹¹) complex can be observed by one-dimensional $^1\text{H-NMR}$. The given region of the spectra shows the aromatic histidine and tryptophan signals for a titration of 30 μM peptide with copper bisglycinate, in 25 mM phosphate buffer, pH 7.4. The mole fraction of copper added is shown on the left. Signals from the four histidine residues in the octapeptide repeats are overlapped so only combined signals are observable. Addition of copper causes specific broadening of the two histidine imidazole signals, with reduced broadening observed for the tryptophan indole signals.

ion. Co-ordination by four imidazoles is consistent with the observed 1:1 stoichiometry of the highest-affinity binding event. The CD response arises from copper (II) co-ordination in a chiral environment, which, in this case, occurs predominantly due to the chiral C_{α} centre between the co-ordinating imidazole and backbone amide of the histidine residue. In a multiple-imidazoleco-ordinated species, the metal ion would be substantially further from this chiral centre compared with co-ordination through both the imidazole and the backbone amide. Thus the weak CD signal observed for the 1:1 complex is also consistent with multiple histidine co-ordination. Finally, imidazole-only co-ordination would be substantially less pH-sensitive than backbone amide coordination owing to the lower pK_a of the imidazole group. If the pH is below the p K_a of a co-ordinating group in a metal-binding site, the affinity of the site is reduced by a factor of ten for each pH unit below the p K_a . Since the p K_a of the imidazole group is approx. 6, and the site is believed to contain four imidazole groups, the affinity of the complex would be expected to be reduced by a factor of about a hundred [i.e. $10^{4\times(6.0-5.5)}$] at pH 5.5 relative to pH 7.4. The observed difference is in fact \sim 1000-fold, suggesting that other factors may also be involved.

Low copper occupancy causes self-association of PrP57-91

Although the 1:1 complex does not produce CD bands at visible wavelengths, it is readily observed by a reduction in the intrinsic tryptophan fluorescence of the peptide (Figure 4). We also found that the relative reduction in the fluorescence of PrP^{57–91} that occurs upon titration with copper is dependent on the peptide concentration. The greater degree of fluorescence quenching that occurs at higher peptide concentrations is consistent with a greater fraction of peptide being held in close proximity to a copper (II) ion. The peptide concentration affects both the rate at which fluorescence is quenched by addition of copper, and the fluorescence at the endpoint of the titration, where all the peptide should be in the 1:1 complex, Cu(PrP^{57–91}). A simple explanation for this is that Cu(PrP^{57–91}) can associate with other molecules




Figure 4 $\,\,$ Self-association of the Cu(PrP⁵⁷⁻⁹¹) complex is demonstrated by fluorescence quenching

The quenching of the intrinsic fluorescence, which occurs on formation of 1:1 complexes of copper and PrP^{57-91} in 5 mM Tris buffer, pH 7.4, is dependent on peptide concentration. Samples of PrP^{57-91} were titrated with copper, with peptide concentrations of 3 μ M (\bigcirc), 1 μ M (\blacksquare) and 0.03 μ M (\triangle).

of apo-peptide, at low copper concentrations, or with other Cu(PrP^{57–91}) complexes. Since the changes in the fluorescence-quenching behaviour are seen on increasing the peptide concentration from 30 nM to 1 μ M, the apparent dissociation constant for the self-association process will be within this range. It is likely that copper (II) will dissociate from these self-associated peptide complexes more slowly than from the monomeric complex. If this is the case, the self-association process will enhance the apparent affinity of copper (II) binding in the 1:1 complex. Indeed, at 30 nM peptide, the titration data show half maximal binding at a copper concentration of approx. 4 μ M, whereas, at a peptide concentration of 1 μ M, it was 1.5 μ M.

PrP^{57-91} can co-ordinate two copper (II) ions with intermediate affinity

Equilibrium dialysis carried out in Mops buffer at pH 7.4, where the copper was presented as a glycine chelate, revealed a clear 2:1 stoichiometry (Figure 5A). In this case, the two sites have identical apparent dissociation constants of $6\pm 2~\mu\mathrm{M}$ and, given stepwise dissociation constants for copper bisglycinate of 1.2 $\mu\mathrm{M}$ and 12 $\mu\mathrm{M}$ [37], a true dissociation constant of $250\pm 50~\mathrm{nM}$. In contrast with the 1:1 complex formed in Tris buffer, the CD spectrum of the 1:1 complex formed in this buffer had clear bands in the visible region at 350 and 580 nm (Figure 5C), indicating a different mode of copper (II) co-ordination.

We judged that the most probable cause of the alternative copper co-ordination in this 1:1 complex was an interaction between the peptide and the Mops buffer which interferes with copper co-ordination; we had observed previously that the peptide is insoluble in the presence of Mes (chemically similar to Mops) at pH 5.5, whereas it is soluble in other buffers at the same pH (results not shown). To test the proposal that the peptide interacts with Mops, a sample of the peptide was titrated with Mops buffer at pH 7.4 and observed by NMR. Chemical-shift changes were indeed observed for the aromatic histidine signals (Figure 5B), confirming that an interaction does occur and that the bound species is significantly occupied at a Mops concentration of 50 mM, equivalent to that present in the equilibrium dialysis and CD experiments described above.

The CD spectrum of the 2:1 complex formed in Mops buffer has peaks at the same wavelengths as the 1:1 complex, but with




Figure 5 A $\text{Cu}_2(\text{Pr}^{97-91})$ complex with a mode of binding distinct from that of both the 1:1 and 4:1 complexes

In Mops buffer, with copper presented as a glycine chelate, the high-affinity 1:1 complex of PrP^{57-91} is disfavoured and two identical sites are observed. (A) Scatchard plot of an equilibrium dialysis experiment in 50 mM Mops buffer at pH 7.4, shows two sites (intercept = 1.94) of equal affinity, each with an apparent dissociation constant of $6\pm1~\mu M$. (B) Titration with Mops causes changes in the chemical shift of signals from the PrP^{57-91} peptide, indicating a weak interaction with the peptide. The change in the chemical shift of the histidine $H\epsilon 1$ signal of PrP^{57-91} is shown. To eliminate the possibility that pH effects were responsible for these changes the experiments were carried out in phosphate buffer at two different concentrations: 25 mM (O) and 50 mM (\bullet). (C) The mode of copper binding observed in Mops buffer gave a clear CD spectrum even at 1:1 stoichiometry. Spectra were recorded for an 11 μ M sample of peptide in 50 mM Mops and 10 μ M glycine, pH 7.4, with one copper (II) ion bound (2:1 CuSO4 and 100 μ M free copper bisglycinate), and with two copper (II) ion bound (2:1 CuSO4 and 100 μ M free copper bisglycinate). Addition of copper bisglycinate to 300 μ M produced no further change in the spectra, indicating that binding was saturated under these conditions at a stoichiometry of 2:1. The CD bands produced by the complexes formed in Mops buffer were similar to those observed in the 4:1 complex formed in NEM buffer at pH 7.4.

twice the intensity, again implying that the two sites are identical. Interestingly, the positions of these CD bands are very similar to those seen previously for the Cu₄(PrP⁵⁷⁻⁹¹) complex in NEM buffer at pH 7.4. The relative signal intensity of the Cu₂(PrP⁵⁷⁻⁹¹) complex in Mops is also comparable with that seen for the Cu₄(PrP⁵⁷⁻⁹¹) complex, suggesting a similar mode of metal coordination. However, the metal co-ordination cannot be identical, since binding of PrP⁵⁷⁻⁹¹ in Mops saturates at a stoichiometry of 2:1 rather than 4:1 and the two sites are of sufficiently high affinity to form in the presence of glycine.

Simulations of copper binding to PrP⁵⁷⁻⁹¹ with three modes of co-ordination

To test the counterintuitive conclusion that, when the two forms of binding are mutually exclusive, four weak copper (II)-binding sites can out-compete a single higher-affinity site, we have used our experimentally derived dissociation constants to simulate the populations of the different species over a range of total




Figure 6 Simulation of three mutually exclusive copper (II)-binding modes in PrP^{57-91}

The concentrations of the main species present at equilibrium in simulations of competing modes of copper binding in PrP^{57–91} are shown over a range of total copper (II) concentrations. The simulations are described in detail in the text. They show that a single site of 3 nM affinity (mode A: Cu^AP) will predominate over four sites of 1 μ M affinity (mode C: Cu^CP, Cu^C $_2$ P, etc.) only at low copper (II) concentrations. The concentrations of the Cu^BP and Cu^CP species did not exceed 1 μ M at any point and are excluded for clarity. For illustration, an approximate predicted CD signal at 580 nM is shown, assuming that each copper (II) ion bound in modes B and C produces an equal signal at this wavelength and that ions bound in mode A produce no signal.

copper (II) concentrations (Figure 6). The following equilibrium was modelled, where three mutually exclusive modes of binding are possible, which here are labelled A, B and C:

$$\begin{array}{ccc} Cu^AP \leftrightarrow & P & \leftrightarrow Cu^cP \leftrightarrow Cu^c{}_2P \leftrightarrow Cu^c{}_3P \leftrightarrow Cu^c{}_4P \\ & \updownarrow & \\ & Cu^BP \\ & \updownarrow & \\ & Cu^B{}_2P \end{array}$$

A dissociation constant of 3 nM was used for the single site present in mode A and a microscopic dissociation constant of 250 nM for each of the two independent sites available in mode B, both based on our experimental measurements. A microscopic dissociation constant of 1 μ M was used for each of the four independent sites available in mode C, based on literature reports of the affinity of this mode of binding [32]. The total peptide concentration was set to 30 μ M to be equivalent to the CD experiments shown in Figure 1. With 1 molar equivalent of Cu²⁺, 94 % of the peptide was in the high-affinity Cu^AP complex, which represents the multiple-histidine-co-ordinated complex that we have described. When the total copper concentration was increased, the higherstoichiometry lower-affinity binding becomes dominant; with 5 molar equivalents of Cu²⁺ present, 97 % of the peptide was in either the Cu^C₃P or the Cu^C₄P form, which represent complexes where each copper ion is co-ordinated by deprotonated backbone amides and a single histidine imidazole. The model therefore supports the assertion that four binding sites of micromolar affinity can out-compete a single site of nanomolar affinity. Furthermore, if the presence of the mode A species was not taken into account, the populations of the mode C species would appear to show cooperative binding. The population of the two intermediate-affinity sites (mode B: Cu^BP, Cu^B₂P), with 250 nM affinity, does not exceed 15% of the total peptide concentration at any point. It is




Figure 7 Equilibrium dialysis reveals two distinct forms of copper (II) coordination in PrP^{91-115}

Scatchard plots of equilibrium dialysis data for PrP^{91-115} show copper (II) binding with stoichiometries of 0.5:1 or 2:1, depending on the solution conditions. (**A**) In 50 mM Mops buffer at pH 7.4, with copper presented as a glycine complex, two sites (intercept = 2.11) of equal affinity are observed, each with an apparent dissociation constant of 5.5 \pm 0.5 μ M. (**B** and **C**)The formation of a 0.5:1 complex gives a non-linear Scatchard plot. The data were dumerically as described in the text, the results of which are represented as continuous lines. Dialysis against CuSO₄ in 5 mM Tris, pH 7.4 (**B**), showed formation of a Cu(PrP^{91-115})₂ complex at low copper concentrations and a Cu_2PrP^{91-115} complex at higher copper concentrations. In 10 mM acetate, pH 5.5, only the $Cu(PrP^{91-115})_2$ complex was observed (**C**). (**D**) CD spectra could be observed for both the $Cu(PrP^{91-115})_2$ and the $Cu_2(PrP^{91-115})$ complex. The spectra of the $Cu(PrP^{91-115})_2$ complex formed in 5 mM Tris buffer, pH 7.4 (100 μ M PrP^{91-115} , 60 μ M $CuSO_4$, i.e. 0.5:1 $CuSO_4$ and 10 μ M free $CuSO_4$) and the $Cu(PrP^{91-115})_2$ complex formed in 0 mM acetate, pH 5.5, are indicated (100 μ M PrP^{91-115} , 1 mM $CuSO_4$). The spectrum of the Cu_2PrP^{91-115} complex formed at pH 7.4 in 50 mM Mops is also shown (60 μ M PrP^{91-115} , 200 μ M copper bisglycinate).

possible that the intermediate-affinity form of binding (mode B) is stronger than we have estimated. If the interaction of the peptide with the Mops buffer competes against this mode of binding, then the dissociation constant will be lower than 250 nM in the absence of Mops.

At maximum occupancy, PrP91-115 can bind two copper (II) ions

A similar program of experiments to that described for PrP^{57-91} was carried out on the peptide PrP^{91-115} to determine whether this peptide could also access multiple copper (II)-binding modes. Equilibrium dialysis data for PrP^{91-115} in Mops buffer at pH 7.4 with copper presented as a glycine chelate indicate that two sites of equivalent affinity were present (Figure 7A) with apparent dissociation constants of $6\pm 1~\mu M$ and true dissociation constants of 250 ± 30 nM. The CD spectrum of the $Cu_2(PrP^{91-115})$ complex which forms in Mops buffer (Figure 7D) was very similar to that reported by Jones et al. [26] with a large positive band at approx. 500 nm. It has been demonstrated by others that this complex

Table 2 Apparent and real dissociation constants for PrP91-115

pН	Buffer	$K_{d(1)}$ (app)	$K_{d(1)}$ (real)	$K_{d(2)}$ (real)	$K_{d(3)}$ (app)	K _{d(3)} (real)
7.4 5.5 7.4	5 mM Tris 10 mM Acetate 50 mM Mops	$30 \pm 10 \; \mu \text{M}$ $1 \pm 0.1 \; \text{mM}$ $6 \pm 1 \; \mu \text{M}$	$100 \pm 50 \text{ nM} \\ 300 \pm 100 \ \mu\text{M} \\ 250 \pm 30 \ \text{nM}$	$5\pm1~\mu{ m M}$ $40\pm10~\mu{ m M}$ $-$	$^{40}{\pm}$ 10 μ M $^{-}$ $^{6}{\pm}$ 1 μ M	$140 \pm 50 \text{ nM} - 250 \pm 30 \text{ nM}$

comprises two copper-binding sites, each involving co-ordination by a single histidine imidazole, from either His⁹⁶ or His¹¹¹, and nearby backbone amide groups [21,26].

PrP⁹¹⁻¹¹⁵ will form a Cu(PrP⁹¹⁻¹¹⁵)₂ complex

We investigated the binding interaction of PrP^{91-115} with copper in Tris buffer at pH 7.4 using equilibrium dialysis, and extrapolation from the first three points of the Scatchard plot shows that the highest-affinity interaction has a stoichiometry of 0.5:1 (Figure 7B). This indicates that, at low copper concentrations, each copper ion forms a complex with two peptide molecules. The equations describing the Scatchard plot for formation of such a species are non-linear. In order to estimate values for the dissociation constants describing the formation of the $Cu(PrP^{91-115})_2$ species, the following equilibrium was modelled:

$$\begin{array}{ccc} P \overset{\kappa_{d(1)}}{\leftrightarrow} & CuP \overset{\kappa_{d(2)}}{\leftrightarrow} CuP_2 \\ & & \updownarrow^{\kappa_{d(3)}} \\ & & Cu_2P \end{array}$$

Using this model, values for the dissociation constants could be fitted to the Scatchard plot, and thus $K_{\rm d(1)}$ was estimated as $30\pm10~\mu{\rm M},~K_{\rm d(2)}$ as $5\pm1~\mu{\rm M}$ and $K_{\rm d(3)}$ as $40\pm10~\mu{\rm M}.$ As the $K_{\rm d(1)}$ and $K_{\rm d(3)}$ values describe the binding of free copper to the peptide, these values are apparent dissociation constants. The true values were then calculated as $100\pm50~\rm nM$ and $140\pm50~\rm nM$ respectively (apparent and true dissociation constants for PrP^{91–115} are summarized in Table 2). The fact that different complexes were again observed in Tris and Mops buffers points to an interaction between the Mops buffer and the peptide that competes against formation of the Cu(PrP^{91–115})₂ complex.

The complexes of PrP^{91-115} with copper were detectable by fluorescence (results not shown). The effects of titration of this peptide with copper were again dependent on the peptide concentration, supporting the other evidence for the existence of the $Cu(PrP^{91-115})_2$ complex.

The mode of copper co-ordination in the $Cu(PrP^{91-115})_2$ complex is pH-dependent

A Cu(PrP⁹¹⁻¹¹⁵)₂ complex will also form at pH 5.5 in 10 mM acetate buffer (Figure 7C). At this pH, there was no evidence of a Cu₂(PrP⁹¹⁻¹¹⁵) complex and therefore a simplified version of the above equilibrium, which did not contain the Cu₂P species, was fitted to the data to give dissociation constants of 1 ± 0.1 mM for $K_{\rm d(1)}$ and of $40 \pm 10~\mu$ M for $K_{\rm d(2)}$. The true value for $K_{\rm d(1)}$ was then calculated as $300 \pm 100~\mu$ M, some 4000-fold weaker at pH 5.5 than at pH 7.4. The amide functional group has a p $K_{\rm a}$ well above 7.4, and so if two deprotonated amides and a single imidazole are involved in co-ordinating the metal ion, then the affinity at pH 5.5 would be a factor of approx. 2×10^4 lower than at pH 7.4 {i.e. $10^{(2 \times (7.4-5.5))+(6.0-5.5)}$ }. The fact that the reduction in affinity was not this great could indicate that, at pH 5.5, the dominant

Cu(PrP^{91–115}) species is a complex with co-ordination from two histidine imidazole groups. The binding of a second peptide to the Cu(PrP^{91–115}) complex to give Cu(PrP^{91–115})₂ was approx. 10-fold weaker at pH 5.5 than at pH 7.4; this would be consistent with co-ordination of the copper (II) ion by two imidazoles from the second peptide, since pH 5.5 is 0.5 units below the histidine imidazole pK_a . Interestingly, at pH 5.5, the second peptide bound with higher affinity than the first, an observation which could be rationalized if a direct interaction between the peptides stabilized the Cu₂P species.

The $Cu(PrP^{91-115})_2$ complexes at pH 7.4 and pH 5.5 both produced a CD signal at visible wavelengths (Figure 7D), but the spectra are not identical, indicating that copper (II) coordination is affected by pH. If these spectra were normalized by the concentration of bound copper instead of by the concentration of peptide, the band at 525 nm would be similar to the bands seen in the $Cu_2(PrP^{91-115})$ complex. This would be consistent with some backbone amide co-ordination occurring in the $Cu(PrP^{91-115})_2$ complexes.

Investigation of the Cu(PrP⁹¹⁻¹¹⁵)₂ complex by NMR

In an effort to confirm which functional groups were involved in co-ordinating copper in the Cu(PrP⁹¹⁻¹¹⁵)₂ complex, a titration of the peptide with copper (II) was observed by NMR, similar to that already described for PrP^{57–91}. In this titration, signals originating from both histidine imidazole side chains were observed to broaden simultaneously as copper was added to the sample (Figure 8A), indicating that they are both involved in the Cu(PrP⁹¹⁻¹¹⁵)₂ complex. The relative populations of free peptide and the different metal complexes can be predicted on the basis of the dissociation constants fitted to the equilibrium dialysis data (Figure 8B). The total integral of the H δ 2 signal did not decrease on addition of copper to the same extent as the population of free peptide. This must be because not all the histidine signals in the $Cu(PrP^{91-115})_2$ complex are broadened beyond detection. This would be the case if, of the four histidine residues in the two peptides, one or two did not directly co-ordinate copper. At least two histidine signals must become undetectable in the Cu(PrP91-115)2 complex; if only one was affected, the reduction in signal in the first part of the titration would be about half that observed. In summary, in the Cu(PrP⁹¹⁻¹¹⁵)₂ complex, the copper (II) ion must be co-ordinated by either two or three histidine side chains, and probably also with a contribution from deprotonated backbone amides.

DISCUSSION

The four octapeptide repeats in the peptide PrP^{57–91} can bind copper in at least three different ways (Figure 9A). This has recently been reported by other investigators who have used EPR data to show that three species exist and to propose the mode of co-ordination in each [31]. Our data support their proposals and allow us to build on the work in several important ways. We have been able to directly estimate the affinity of the two




Figure 8 NMR of PrP91-115 copper (II) complexes

Formation of the $Cu(PrP^{91-115})_2$ complex can be observed by one-dimensional 1H -NMR, with broadening of the H_E1 signals of the two histidine residues, indicating that they are both involved in copper co-ordination. (**A**) Spectra are shown for a titration of $100~\mu$ M PrP^{91-115} with copper (II), in 5 mM Tris buffer, pH 7.4, with the mole fraction of copper (II) added shown in the left. (**B**) The predicted fractions of free peptide (solid line) and peptide in the $Cu(PrP^{91-115})_2$ complex (broken line), based on the equilibrium dialysis data, show that the $Cu(PrP^{91-115})_2$ is the dominant species below 1:1 stoichiometry. The integral of the histidine $H\delta 2$ signal (\bigcirc) is plotted relative to its starting value on the same axes.

higher affinity modes of copper (II) binding. We have shown that self-association of the octapeptide repeats plays a role in the highest affinity, multiple-histidine-co-ordination mode. We have also defined conditions under which the two intermediate-affinity sites are the only species present, which was reported to be an obstacle to further spectroscopic investigation of this species by Chattopadhyay et al. [31]. The CD spectra that we were able to acquire for the Cu₂(PrP^{57–91}) complex support the proposal that the copper is co-ordinated in this complex in a similar way to the Cu₄(PrP^{57–91}) complex, but with an additional axially co-ordinated histidine.

From our data, it is also clear that at least two forms of copper co-ordination occur in the peptide PP^{91-115} (Figure 9B). At maximum occupancy, two sites are observed which both involve co-ordination by a histidine imidazole and deprotonated backbone amides. The affinities of these two sites are similar, indeed they could be the same within error, and are in the range 100-200 nM. The $Cu(PrP^{91-115})$ complex binds a second peptide with an affinity of approx. 5 μ M; an affinity this high suggests that the second peptide is acting as a bidentate ligand because a single imidazole only binds to copper with a dissociation constant of approx. $60~\mu$ M [37]. The pH-dependence of this interaction also supports the idea that two imidazoles from the second peptide co-ordinate the copper (II) ion. The interaction could take the form of axial co-ordination from two imidazole groups or could involve the displacement of some of the backbone amides that co-ordinate copper in the $Cu(PrP^{91-115})$ complex.

The existence of the Cu(PrP⁹¹⁻¹¹⁵)₂ complex strongly suggests that the copper ion in the Cu(PrP⁹¹⁻¹¹⁵) complex has spare coordination sites that can bind a second peptide molecule through its histidine residues. As such, the peptide PrP⁹¹⁻¹¹⁵ can not be considered a complete model of copper (II) binding in the full-length protein, where additional histidine side chains would be available

to fill any spare co-ordination sites. Likewise, the self-associative behaviour of the Cu(PrP^{57–91}) complex could be explained if there were spare co-ordination sites on the metal ion that allowed intermolecular complexes to form. Again, in the full-length protein, with additional histidine side chains available, extra co-ordinating groups may be involved in the complex. If this were the case, affinities in the full-length protein would be higher than those measured in the peptide models used in the present study.

Our observations of multiple copper (II) co-ordination modes in the octapeptide repeats explain discrepancies in the literature about the stoichiometry of copper (II) binding in the octapeptide repeats and in the full-length protein. As described above, most studies have reported that the four octapeptide repeats bind four copper (II) ions with micromolar affinities at pH 7.4 [15,20,23]. Likewise, a stoichiometry of 5.2 ± 1.1 has been observed for the full-length PrP at pH 7.4 [21]. These high-occupancy-binding modes, which have affinities in the micromolar range, will only occur in the absence of competition for copper (II) from chelating agents, such as Tris or glycine. Studies that use conditions that compete against the high-occupancy copper (II)-binding modes, such as amino acid competition or gel-filtration chromatography, have reported that the four octapeptide repeats can bind only a single copper (II) ion [12,25]. Similarly, mildly acidic pH will disfavour the deprotonation of backbone amides which is required for high-occupancy binding; at pH 6.0, the full-length protein is found to bind just two copper ions [33], instead of the five or six at pH 7.4. It is now clear that these low-occupancy copper (II)-binding modes involve co-ordination from multiple histidine imidazoles, which allows the sites to be maintained at lower pH, and that they have affinities in the low-nanomolar range, which is sufficiently strong for the site to remain intact in the presence of competition from chelating agents with micromolar affinities.

The total copper concentration in serum is $16-20 \mu M$, all of which exists as complexes, the majority with caeruloplasmin and the remainder with other proteins (including transcuprein and albumin), peptides and amino acids [34], and the concentration of free copper (i.e. an aqua complex) is therefore virtually nil. On the cell surface in brain tissue, PrP would equilibrate with the extracellular pool of copper available in the brain interstitial fluid, which is in equilibrium with the CSF (cerebrospinal fluid). In healthy subjects, the copper concentration in the CSF is of the order of 0.1 μ M [38], and, again, this is expected to exist as complexes with albumin, caeruloplasmin or amino acids. Therefore, in determining whether PrP is an authentic cuproprotein, its affinity should be compared with the affinities of the other copper-binding species in the extracellular milieu, with which it must compete for copper, and not the total copper concentration. The dissociation constant of human albumin for copper (II) is approx. 10 pM [35], whereas the stepwise dissociation constants for the formation of a copper bis-histidinate complex at pH 7.4 are approx. 4 nM and 0.5 μ M [37]. Histidine is present at approx. $10 \,\mu\text{M}$ in the CSF, and albumin is present at approx. $20 \,\text{mg/dl}$ which equates to about 3 μ M. Thus both these species are well in excess of the total copper (II) concentration and have similar or higher affinities than the peptide models of the prion protein that we have studied. Our measured affinities therefore suggest that only a small fraction of PrP, if any, is likely to bind copper under normal conditions in the central nervous system. However, during neuronal depolarization, the copper concentration at the synapse increases; one estimate places this increase as approx. 15 μ M, with approx. 20 % of this is in complexes with dissociation constants weaker than 100 nM [39]. It is thus likely that PrP could bind copper only when levels are elevated during neuronal depolarization. Even under this circumstance, however, probably only the higher-affinity binding modes would be populated due

Figure 9 Multiple modes of copper binding in PrP

(A) At least three different modes of copper (II) co-ordination occur within the octapeptide repeats at pH 7.4. Models for the structure of each mode of binding based on our data and those of others are shown, alongside estimates for the dissociation constants. The cartoons represent the peptide backbone in the peptide PrP⁵⁷⁻⁹¹, with the histidine side chains shown as pentagons and the copper (II) ion represented by the black circle. (B) The structure for the Cu(PrP⁹¹⁻¹¹⁵) and Cu₂(PrP⁹¹⁻¹¹⁵) complexes is shown as described in the literature (left). At present, there are insufficient data to propose a detailed structure for the Cu(PrP⁹¹⁻¹¹⁵)₂ complex, although our NMR data indicate that either two or three of the available histidine residues are involved in co-ordinating the metal ion (right). Estimates of the dissociation constants are given for all the complexes based on our measurements with the exception of the lowest binding affinity shown in (A) which is based on reports in the literature. The cartoons represent the peptide backbone and the side chains of His⁹⁶ and His¹¹¹. At present, it is not possible to distinguish whether either histidine is favoured for any particular co-ordination position.

to the excess of other species which can bind copper (II) with micromolar or higher affinities.

The present study also raises the possibility that the elevated copper levels which occur during neuronal depolarization could play a role in controlling self-association of PrP *in vivo*, if the effective molarity of PrP on the cell surface is higher than approx. 100 nM. Any factor that could influence the self-association of PrP *in vivo* is of potential importance in understanding the normal function of PrP^c and its role in prion disease and thus would merit further investigation.

This work was funded by the U.K. Medical Research Council and Biotechnology and Biological Sciences Research Council. We would like to thank Ray Young for the preparations of Figures, Neil Brammal for assistance with ICP-atomic emission spectrometry, Andrea Hounslow for assistance with NMR spectroscopy and Matthew Cliff and Rosie Staniforth for critical reading of the manuscript.

REFERENCES

- 1 Collinge, J. (2001) Prion diseases of humans and animals: their causes and molecular basis. Annu. Rev. Neurosci. 24, 519–550
- 2 Griffith, J. S. (1967) Self-replication and scrapie. Nature 215, 1043-1044

- 3 Prusiner, S. B. (1982) Novel proteinaceous infectious particles cause scrapie. Science 216, 136–144
- 4 Stahl, N., Borchelt, D. R., Hsiao, K. and Prusiner, S. B. (1987) Scrapie prion protein contains a phosphatidylinositol glycolipid. Cell 51, 229–240
- 5 Riek, R., Hornemann, S., Wider, G., Billeter, M., Glockshuber, R. and Wüthrich, K. (1996) NMR structure of the mouse prion protein domain PrP(121–321). Nature 382, 180–182
- 6 Zahn, R., Liu, A. Z., Luhrs, T., Riek, R., von Schroetter, C., Garcia, F. L., Billeter, M., Calzolai, L., Wider, G. and Wüthrich, K. (2000) NMR solution structure of the human prion protein. Proc. Natl. Acad. Sci. U.S.A. 97, 145–150
- 7 Bendheim, P. E., Brown, H. R., Rudelli, R. D., Scala, L. J., Goller, N. L., Wen, G. Y., Kascsak, R. J., Cashman, N. R. and Bolton, D. C. (1992) Nearly ubiquitous tissue distribution of the scrapie agent precursor protein. Neurology 42, 149–156
- 8 Dodelet, V. C. and Cashman, N. R. (1998) Prion protein expression in human leukocyte differentiation. Blood 91, 1556–1561
- 9 Bueler, H., Fischer, M., Lang, Y., Bluethmann, H., Lipp, H. P., Dearmond, S. J., Prusiner, S. B., Aguet, M. and Weissmann, C. (1992) Normal development and behavior of mice lacking the neuronal cell-surface Prp Protein. Nature 356, 577–582
- 10 Collinge, J., Whittington, M. A., Sidle, K. C. L., Smith, C. J., Palmer, M. S., Clarke, A. R. and Jefferys, J. G. R. (1994) Prion protein is necessary for normal synaptic function. Nature 370, 295–297
- 11 Tobler, I., Gaus, S. E., Deboer, T., Achermann, P., Fischer, M., Rulicke, T., Moser, M., Oesch, B., McBride, P. A. and Manson, J. C. (1996) Altered circadian activity rhythms and sleep in mice devoid of prion protein. Nature 380, 639–642

- Hornshaw, M. P., McDermott, J. R. and Candy, J. M. (1995) Copper-binding to the N-terminal tandem repeat regions of mammalian and avian prion protein. Biochem. Biophys. Res. Commun. 207, 621–629
- Hornshaw, M. P., McDermott, J. R., Candy, J. M. and Lakey, J. H. (1995) Copper-binding to the N-terminal tandem repeat region of mammalian and avian prion protein: structural studies using synthetic peptides. Biochem. Biophys. Res. Commun. 214, 993—999
- 14 Qin, K. F., Yang, Y., Mastrangelo, P. and Westaway, D. (2002) Mapping Cu(II) binding sites in prion proteins by diethyl pyrocarbonate modification and matrix-assisted laser desorption ionization-time of flight (MALDI-TOF) mass spectrometric footprinting. J. Biol. Chem. 277, 1981–1990
- 15 Whittal, R. M., Ball, H. L., Cohen, F. E., Burlingame, A. L., Prusiner, S. B. and Baldwin, M. A. (2000) Copper binding to octarepeat peptides of the prion protein monitored by mass spectrometry. Protein Sci. 9, 332–343
- 16 Brown, D. R., Qin, K. F., Herms, J. W., Madlung, A., Manson, J., Strome, R., Fraser, P. E., Kruck, T., von Bohlen, A., Schulz-Schaeffer, W. et al. (1997) The cellular prion protein binds copper *in vivo*. Nature **390**, 684–687
- 17 Waggoner, D. J., Drisaldi, B., Bartnikas, T. B., Casareno, R. L. B., Prohaska, J. R., Gitlin, J. D. and Harris, D. A. (2000) Brain copper content and cuproenzyme activity do not vary with prion protein expression level. J. Biol. Chem. 275, 7455–7458
- 18 Rachidi, W., Vilette, D., Guiraud, P., Arlotto, M., Riondel, J., Laude, H., Lehmann, S. and Favier, A. (2003) Expression of prion protein increases cellular copper binding and antioxidant enzyme activities but not copper delivery. J. Biol. Chem. 278, 9064–9072
- 19 Pauly, P. C. and Harris, D. A. (1998) Copper stimulates endocytosis of the prion protein. J. Biol. Chem. 273, 33107–33110
- 20 Aronoff-Spencer, E., Burns, C. S., Avdievich, N. I., Gerfen, G. J., Peisach, J., Antholine, W. E., Ball, H. L., Cohen, F. E., Prusiner, S. B. and Millhauser, G. L. (2000) Identification of the Cu²⁺ binding sites in the N-terminal domain of the prion protein by EPR and CD spectroscopy. Biochemistry 39, 13760–13771
- 21 Burns, C. S., Aronoff-Spencer, E., Legname, G., Prusiner, S. B., Antholine, W. E., Gerfen, G. J., Peisach, J. and Millhauser, G. L. (2003) Copper coordination in the full-length, recombinant prion protein. Biochemistry 42, 6794–6803
- 22 Bonomo, R. P., Imperllizzeri, G., Pappalardo, G., Rizzarelli, E. and Tabbi, G. (2000) Copper(II) binding modes in the prion octapeptide PHGGGWGQ: a spectroscopic and voltammetric study. Chemistry 6, 4195–4202
- 23 Viles, J. H., Cohen, F. E., Prusiner, S. B., Goodin, D. B., Wright, P. E. and Dyson, H. J. (1999) Copper binding to the prion protein: Structural implications of four identical cooperative binding sites. Proc. Natl. Acad. Sci. U.S.A. 96, 2042–2047
- 24 Burns, C. S., Aronoff-Spencer, E., Dunham, C. M., Lario, P., Avdievich, N. I., Antholine, W. E., Olmstead, M. M., Vrielink, A., Gerfen, G. J., Peisach, J. et al. (2002) Molecular features of the copper binding sites in the octarepeat domain of the prion protein. Biochemistry 41, 3991–4001

Received 16 May 2006/20 July 2006; accepted 22 August 2006 Published as BJ Immediate Publication 22 August 2006, doi:10.1042/BJ20060721

- 25 Jackson, G. S., Murray, I., Hosszu, L. L. P., Gibbs, N., Waltho, J. P., Clarke, A. R. and Collinge, J. (2001) Location and properties of metal-binding sites on the human prion protein. Proc. Natl. Acad. Sci. U.S.A. 98, 8531–8535
- 26 Jones, C. E., Klewpatinond, M., Abdelraheim, S. R., Brown, D. R. and Viles, J. H. (2005) Probing copper²⁺ binding to the prion protein using diamagnetic nickel²⁺ and ¹H NMR: the unstructured N terminus facilitates the coordination of six copper²⁺ ions at physiological concentrations. J. Mol. Biol. **346**, 1393–1407
- 27 Miura, T., Hori-i, A., Mototani, H. and Takeuchi, H. (1999) Raman spectroscopic study on the copper(II) binding mode of prion octapeptide and its pH dependence. Biochemistry 38, 11560–11569
- 28 Miura, T., Sasaki, S., Toyama, A. and Takeuchi, H. (2005) Copper reduction by the octapeptide repeat region of prion protein: pH dependence and implications in cellular copper uptake. Biochemistry 44, 8712–8720
- 29 Gustiananda, M., Haris, P. I., Milburn, P. J. and Gready, J. E. (2002) Copper-induced conformational change in a marsupial prion protein repeat peptide probed using FTIR spectroscopy. FEBS Lett. 512, 38–42
- 30 Valensin, D., Luczkowski, M., Mancini, F. M., Legowska, A., Gaggelli, E., Valensin, G., Rolka, K. and Kozlowski, H. (2004) The dimeric and tetrameric octarepeat fragments of prion protein behave differently to its monomeric unit. Dalton Trans. 1284–1293
- 31 Chattopadhyay, M., Walter, E. D., Newell, D. J., Jackson, P. J., Aronoff-Spencer, E., Peisach, J., Gerfen, G. J., Bennett, B., Antholine, W. E. and Millhauser, G. L. (2005) The octarepeat domain of the prion protein binds Cu(II) with three distinct coordination modes at pH 7.4. J. Am. Chem. Soc. 127, 12647–12656
- 32 Kramer, M. L., Kratzin, H. D., Schmidt, B., Romer, A., Windl, O., Liemann, S., Hornemann, S. and Kretzschmar, H. (2001) Prion protein binds copper within the physiological concentration range. J. Biol. Chem. 276, 16711–16719
- 33 Stockel, J., Safar, J., Wallace, A. C., Cohen, F. E. and Prusiner, S. B. (1998) Prion protein selectively binds copper(II) ions. Biochemistry 37, 7185–7193
- 34 Linder, M. C. (1991) Extracellular copper substituents and mammalian copper transport. In Biochemistry of Copper, pp. 73–134, Plenum Press, New York
- Masuoka, J., Hegenauer, J., Vandyke, B. R. and Saltman, P. (1993) Intrinsic stoichiometric equilibrium-constants for the binding of zinc(II) and copper(II) to the high-affinity site of serum-albumin. J. Biol. Chem. 268, 21533–21537
- 36 Perrin, D. D. (1979) Stability Constants of Metal–Ion Complexes. Part B: Organic Ligands, IUPAC Chemical Data Series No. 22, Pergamon Press, Oxford
- 37 Dawson, R. M. C., Elliott, D. C., Elliott, W. H. and Jones, K. M. (1986) Stability constants for metal complexes. In Data for Biochemical Research, pp. 399–416, Oxford University Press. Oxford
- 38 Joergstuerenburg, H., Oechsner, M., Schroeder, S. and Kunze, K. (1999) Determinants of the copper concentration in cerebrospinal fluid. J. Neurol. Neurosurg. Psychiatry 67, 252–253
- 39 Hopt, A., Korte, S., Fink, H., Panne, U., Niessner, R., Jahn, R., Kretzchmar, H. and Herms, J. (2003) Methods for studying synaptosomal copper release. J. Neurosci. Methods 128, 159–172